DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the stock.

Other analysts have also issued reports about the stock. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of DBV Technologies in a research note on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of DBV Technologies in a research report on Thursday, August 1st.

DBV Technologies Trading Up 0.8 %

Shares of NASDAQ DBVT opened at $0.70 on Friday. The company has a market cap of $67.45 million, a price-to-earnings ratio of -0.83 and a beta of 0.67. The stock’s 50 day simple moving average is $0.81 and its 200 day simple moving average is $1.00. DBV Technologies has a 12-month low of $0.50 and a 12-month high of $2.40.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period last year, the business earned ($0.26) EPS. As a group, equities analysts forecast that DBV Technologies will post -1.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. increased its position in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the period. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.